Compare Cardinal Health Inc (CAH) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Rocket Lab USA Inc — how do they compare? Cardinal Health Inc trades at $234.2 (market cap $55.88B), while Rocket Lab USA Inc trades at $80.92 (market cap $50.01B). The key difference: Cardinal Health Inc and Rocket Lab USA Inc are close in size by market cap, and Cardinal Health Inc pays a 0.86% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| CAH | RKLB | |
|---|---|---|
Market Cap | $55.88B | $50.01B |
Sector | Health | Technology |
52-Week High | $240.26 | $150.23 |
52-Week Low | $146.04 | $39.48 |
Enterprise Value | $59.91B | $47.84B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
Rocket Lab (RKLB) trades at $81.17, up 1.41% today, showing strong momentum with a bullish technical outlook. The company reported record Q2 2026 revenue of $601.8M but missed EPS expectations, while maintaining a massive $2.36B backlog. Analysts remain overwhelmingly bullish with a $118 consensus target, though valuation metrics appear stretched with a P/S ratio of 60.8.
The stock offers significant upside potential driven by Neutron rocket development and growing space industry demand, but faces execution risks including margin pressures and cash burn. Near-term catalysts include the Neutron launch timeline and Iridium acquisition, though high valuation multiples require flawless execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
